Boothbay Fund Management LLC Invests $1.34 Million in Pfizer Inc. (NYSE:PFE)

Boothbay Fund Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, HoldingsChannel reports. The firm purchased 50,336 shares of the biopharmaceutical company’s stock, valued at approximately $1,335,000.

Other large investors also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $34,536,000. Coldstream Capital Management Inc. raised its position in Pfizer by 110.1% during the fourth quarter. Coldstream Capital Management Inc. now owns 227,323 shares of the biopharmaceutical company’s stock worth $6,031,000 after acquiring an additional 119,111 shares during the period. Capital Analysts LLC lifted its holdings in Pfizer by 16.1% during the fourth quarter. Capital Analysts LLC now owns 24,656 shares of the biopharmaceutical company’s stock valued at $654,000 after purchasing an additional 3,424 shares in the last quarter. Arnhold LLC grew its position in shares of Pfizer by 16.3% in the fourth quarter. Arnhold LLC now owns 758,746 shares of the biopharmaceutical company’s stock valued at $20,130,000 after purchasing an additional 106,267 shares during the period. Finally, Pingora Partners LLC increased its stake in shares of Pfizer by 24.6% during the fourth quarter. Pingora Partners LLC now owns 84,718 shares of the biopharmaceutical company’s stock worth $2,248,000 after purchasing an additional 16,748 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.57.

Pfizer Stock Up 0.5 %

Shares of NYSE PFE opened at $23.04 on Tuesday. The company has a market capitalization of $130.67 billion, a P/E ratio of 16.34, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a 50 day simple moving average of $24.52 and a 200-day simple moving average of $25.88. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.47%. Pfizer’s payout ratio is currently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.